Generic Medicine Info
Indications and Dosage
Pain and inflammation associated with musculoskeletal and joint disorders, Postoperative pain
Adult: Initially, 120 mg daily in divided doses, may increase to 180 mg, based on patient response.
Renal Impairment
Severe: Contraindicated.
Hepatic Impairment
Severe: Contraindicated.
Should be taken with food. Take w/ or immediately after meals.
Hypersensitivity to acemetacin or indometacin and other NSAIDS. Active or history of peptic ulcer/haemorrhage, history of GI bleeding or perforation related to previous NSAID therapy, blood formation disorder of unclear etiology, nasal polyps (associated w/ angioneurotic oedema), severe heart failure. Severe renal and hepatic impairment. Pregnancy (3rd trimester).
Special Precautions
Patient w/ history of GI toxicity, resp disorder (e.g. asthma, hay fever, swollen nasal mucosae, chronic resp disease), uncontrolled HTN, CHF, ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, hyperlipidaemia, DM, ulcerative colitis, Crohn’s disease, SLE, mixed connective tissue disorders, chickenpox, herpes zoster, parkinsonism. Hepatic and renal impairment. Pregnancy and lactation.
Adverse Reactions
Nausea, vomiting, diarrhoea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastritis; asthma, bronchospasm, dyspnoea; pruritus, urticaria, purpura, angioedema; HTN, oedema, cardiac failure; agitation; headache, dizziness, malaise, drowsiness, increased hepatic enzyme; alopecia; retinal pigment degeneration, corneal opacity. Rarely, pancreatitis, exfoliative and bullous dermatoses (e.g. epidermal necrolysis, erythema multiforme); necrotising fasciitis; hyperglycaemia, glucosuria; hyperkalaemia; irritability, confusion.
Potentially Fatal: GI bleeding, ulceration or perforation. Rarely, severe hypersensitivity reactions, including angioneurotic oedema, resp distress which may lead to asthma attack, tachycardia or decreased BP leading to shock.
Patient Counseling Information
This drug may cause dizziness, drowsiness, fatigue, and visual disturbances, if affected, do not drive or operate machinery.
Monitor haemogram and blood coagulation, liver and kidney function.
Symptoms: Headache, nausea, vomiting, epigastric pain, GI bleeding, diarrhoea, disorientation, excitation, coma, drowsiness, dizziness, tinnitus, fainting, convulsions, acute renal failure, liver damage. Management: Symptomatic and supportive treatment. Employ activated charcoal or gastric lavage w/in 1 hr of ingestion. IV diazepam may be used for frequent or prolonged convulsions.
Drug Interactions
May increase risk of AR w/ other NSAIDs. Increased GI ulceration/bleeding w/ corticosteroids, anti-platelet agents, and SSRIs. Reduced resorption rate w/ antacids. Reduced elimination w/ probenecid, sulfinpyrazone. May reduce the effect of diuretics and antihypertensive agents. May reduce elimination of phenytoin, lithium, methotrexate. Increased risk of nephrotoxicity w/ ciclosporin and diuretics.
Food Interaction
Occult blood loss from GI tract is enhanced by alcohol.
Description: Acemetacin, a glycolic acid ester of indometacin, is a relatively weak inhibitor of prostaglandin synthesis. Additionally, it is involved in the inhibition of the release of inflammatory mediators.
Absorption: Well absorbed after oral admin.
Metabolism: Metabolised into its major metabolite, indometacin.
Excretion: Via liver and kidneys.
Store below 25°C.
ATC Classification
M01AB11 - acemetacin ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.
Anon. Acemetacin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 04/08/2016.

Buckingham R (ed). Acemetacin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 04/08/2016.

Joint Formulary Committee. Acemetacin. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 04/08/2016.

Disclaimer: This information is independently developed by MIMS based on Acemetacin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in